On January 10, Deyuan Pharmaceutical (832735, BJ; yesterday’s closing price was 23.35 yuan) announced that the company planned to issue no more than 8 million shares to specific objects and raise no more than 160 million yuan for capital increase and holding no less than 55% of the equity of Beijing Tongli Haiyuan Biotechnology Co., Ltd. (hereinafter referred to as Tongli Haiyuan).
The reporter of the daily economic news noted that by the end of the third quarter of 2021, the owner’s equity of Tongli Haiyuan was only about 2.89 million yuan, and its net profit in the first three quarters of 2021 was about 750000 yuan.
Deyuan pharmaceutical said that tonglihaiyuan focuses on the development of upstream GMP raw materials in the field of biomedical CGT (cell and gene therapy), is committed to providing reliable products and services for life sciences, and has a complete biomedical R & D, production and sales system.
In December 2021, Deyuan pharmaceutical announced that it had signed an intentional cooperation agreement with Wang Liyan and Tongli Haiyuan, the actual controllers of Tongli Haiyuan, and planned to obtain 55% equity of Tongli Haiyuan by means of capital increase. On January 10, 2022, Deyuan pharmaceutical issued the plan for issuing shares to specific objects in 2022, which plans to raise no more than 160 million yuan to increase the capital of Tongli Haiyuan, so as to obtain the above equity.
Deyuan pharmaceutical announcement shows that up to now, the actual controller of Tongli Haiyuan is Wang Liyan. After the capital increase, the current senior management and core technical personnel of tonglihaiyuan will remain unchanged and perform their existing responsibilities.
It is understood that the above capital increase funds are used for the construction of Tongli Haiyuan Jiangsu Lianyungang Port Co.Ltd(601008) production base, the upgrading of Beijing Daxing R & D center, the upgrading of marketing center and the replenishment of working capital projects.
For the Jiangsu Lianyungang Port Co.Ltd(601008) production base project, Deyuan pharmaceutical said that Tongli Haiyuan’s existing production capacity can no longer meet the supply demand of the market and there is an urgent need for capacity expansion. The construction of the production base of the raised investment project focuses on the improvement of the production capacity of recombinant protein and culture medium.
For the upgrading project of Beijing Daxing R & D center, Deyuan pharmaceutical said that the project will purchase advanced R & D equipment, improve R & D conditions, focus on the upgrading of technical platform and supporting process development.
“This transaction will help the company quickly cut into the field of biomedicine, gradually break the monopoly of foreign brands in the field of medium and high-end biological reagents, and build an industrial layout for the coordinated development of chemical drugs and biological drugs.” Deyuan pharmaceutical said in the announcement.
Deyuan pharmaceutical said that tonglihaiyuan has long focused on the development of upstream GMP core reagents in the field of cell and gene therapy (CGT) in life science, and is committed to providing reliable products and services for life science. It is a high-tech enterprise integrating scientific research, production and operation.
It is worth noting that as of September 30, 2021, Tongli Haiyuan had total assets of about RMB 17.44 million and owner’s equity of about RMB 2.89 million. In the first three quarters of 2021, it realized operating revenue of about RMB 11.17 million and net profit of about RMB 750000.
